China continues industry probe

Share this article:

China's scrutiny of the drug industry continues. The Wall Street Journal reports that Roche announced government authorities from China's State Administration for Industry and Commerce, an agency which oversees marketing and antitrust, visited a site in Hangzhou.

Thursday's news follows last week's announcement that the Ministry of Public Security accused GlaxoSmithKline of bribing HCPs to stimulate prescriptions.

AstraZeneca, Sanofi and Bayer have also come under review over the last year.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.